GO
Loading...

Enter multiple symbols separated by commas

Stocks Celgene Corp

More

  • LONDON, July 30- AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar. Chief Executive Pascal Soriot, who fended off a $118 billion takeover attempt by Pfizer last year, is banking on a promising pipeline of new drugs-...

  • NEW YORK, July 29- Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. Patent and Trademark Office on Tuesday to sanction Bass and others behind the group by throwing out its...

  • *Tecfidera U.S. growth to be flat for rest of 2015. July 24- Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis drug, Tecfidera, to continue slowing this year in the United States. Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the...

  • Celgene beats Street 2Q forecasts Thursday, 23 Jul 2015 | 8:06 AM ET

    SUMMIT, N.J. _ Celgene Corp. on Thursday reported second-quarter earnings of $356.2 million. Celgene expects full-year earnings in the range of $4.75 to $4.85 per share, with revenue in the range of $9 billion to $9.5 billion. Celgene shares have increased 24 percent since the beginning of the year, while the Standard& Poor's 500 index has increased nearly 3...

  • US STOCKS-Wall Street edges lower as energy weighs Wednesday, 15 Jul 2015 | 4:23 PM ET

    *Bank of America rises after profit more than doubles. "We were positive the whole day and we sort of lost our gains right at the tail end," said Phil Orlando, chief equity market strategist at Federated Investors in New York. "If crude were to be going down, that would mean there is an assumption this deal may get through Congress or the President's veto won't get...

  • *Bank of America rises after profit more than doubles. Brent settled down $1.46 at $57.05 while U.S. crude settled down $1.63 at $51.41 a barrel. The group was buoyed by a 3.4 percent rise in Bank of America to $17.72 and a 3.7 percent gain in U.S. Bancorp to $45.51 after their quarterly results.

  • US STOCKS-Wall St higher; financial stocks lead Wednesday, 15 Jul 2015 | 1:09 PM ET

    *Nasdaq biotech index hits record high on Celgene deal. Celgene jumped as much as 10.7 percent to a record high of $135.98 after the company said it would buy Receptos to get a potential multibillion-dollar drug. Celgene's gains helped push the Nasdaq biotech index to hit a record high for the third time in three weeks.

  • *Nasdaq biotech index hits record high on Celgene deal. *Bank of America rises after profit more than doubles. *Delta Air Lines warning weighs on airline stocks.

  • *Celgene soars on deal to buy Receptos. Celegene's shares jumped as much as 9.4 percent to a record high of $134.34 after the company said it would buy Receptos for $7.2 billion to get a potential multibillion-dollar drug. Receptos jumped 10.4 percent to $228.64, while the Nasdaq biotech index jumped more than 2 percent to hit a record high for the third time in...

  • *Bank of America rises after profit more than doubles. July 15- Wall Street was set to open little changed on Wednesday after Federal Reserve Chair Janet Yellen said the central bank remained on track to raise interest rates this year, with turmoil abroad unlikely to throw the U.S. economy off track. "The fact that the Fed feels comfortable raising rates even with...

  • Celgene to buy Receptos for $7.3B Wednesday, 15 Jul 2015 | 8:00 AM ET
    Celgene to buy Receptos for $7.3B

    Cancer drug company Celgene agrees to pay $7.3 billion for Receptos.

  • Early movers: BLK, BAC, PRNA, DAL, LNKD & more Wednesday, 15 Jul 2015 | 7:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • This drug was key driver of Celegene deal: CEO Wednesday, 15 Jul 2015 | 7:52 AM ET
    This drug was key driver of Celegene deal: CEO

    CNBC's Meg Tirrell and Robert Hugin, Celgene chairman & CEO, discuss the drugmaker's $7.3 billion bid for Receptos in an effort to acquire a third autoimmune drug.

  • July 15- U.S. stock index futures were little changed on Wednesday as investors await Federal Reserve Chair Janet Yellen's comments on raising interest rates and the outcome of a Greek parliament vote on the terms of a third bailout. *Bank of America's quarterly profit more than doubled as legal costs dropped sharply, driving expenses down to their lowest since...

  • July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics...

  • UPDATE 1-Celgene to buy Receptos for $7.2 bln Tuesday, 14 Jul 2015 | 5:41 PM ET

    July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential blockbuster drug in late stage development for inflammatory bowel disease and multiple sclerosis. The move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics to gain access to...

  • After-hours buzz: Yum, CSX, Celgene & more Tuesday, 14 Jul 2015 | 5:36 PM ET
    Traders work the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Tuesday: Yum, CSX, Celgene & more.

  • Celgene to buy Receptos for $7.2 bln Tuesday, 14 Jul 2015 | 5:15 PM ET

    July 14- Celgene Corp said it agreed to buy Receptos Inc for about $7.2 billion to expand its pipeline with Receptos' immune-inflammatory bowel drug, Ozanimod. Celgene will pay $232 in cash for every Receptos share, representing a 12 percent premium to the company's closing price on Tuesday. Ozanimod is in late-stage trials for inflammatory bowel disease and...

  • Receptos stock soars on deal with Celgene Tuesday, 14 Jul 2015 | 5:02 PM ET
    Abraxane by Celgene

    Celgene announced Tuesday that it will acquire Receptos for $232 per share in cash for a total of about $7.2 billion.

  • AstraZeneca divests gastrointestinal drug for $215 mln Thursday, 9 Jul 2015 | 3:07 AM ET

    LONDON, July 9- AstraZeneca struck a further "externalisation" deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million. The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer,...